Glancy
Binkow & Goldberg LLP announces that a class action lawsuit has
been filed in the United States District Court for the Southern District
of California on behalf of a class (the “Class”) comprising all persons
or entities who purchased the securities of Retrophin, Inc. (“Retrophin”
or the “Company”) (NASDAQ:RTRX) between March 27, 2014 and September 30,
2014, inclusive (the "Class Period"). If you are a shareholder who
purchased Retrophin securities during the Class Period, you have until
December 19, 2014 to ask the Court to appoint you as Lead Plaintiff for
the class.
Please contact Lesley
Portnoy or Casey
Sadler at (888) 773-9224 or (310) 201-9150, or at shareholders@glancylaw.com
to discuss this matter. If you inquire by email please include your
mailing address, telephone number and number of shares purchased.
The complaint against the Company alleges that throughout the Class
Period, Defendants made false and/or misleading statements, and failed
to disclose material adverse facts about the Company's business,
operations, prospects and performance. Specifically, during the Class
Period, Defendants made false and/or misleading statements and/or failed
to disclose that: (i) Retrophin's founder and Chief Executive Officer
was trading Company stock in violation of the Company's Incentive
Compensation Plan and other securities rules; (ii) these trading
irregularities included grants of shares in violation of the Company's
Incentive Compensation Plan and the failure to disclose stock grants to
employees; and (iii) as a result of the above, the Company's statements
were materially false and misleading at all relevant times.
On September 16, 2014, after the close of trading, the Company issued a
press release and filed a Form 8-K with the SEC announcing that on
September 15, 2014, it had reached an agreement with its Chief Financial
Officer, Marc Panoff, pursuant to which Mr. Panoff's employment with the
Company will terminate, effective as of February 28, 2015. Also, the
Company announced that on September 10, 2014, Jeffrey Paley, MD abruptly
stepped down as a member of the Board of Directors. As a result of this
news, shares of Retrophin fell $1.03 or over 8%, on unusually heavy
trading, to close at $11.46 on September 17, 2014.
Furthermore, on September 30, 2014, after the close of trading, the
Company issued a press release announcing that its Board of Directors
terminated its Chief Executive Officer, Martin Shkreli, effective
immediately, and appointed Stephen Aselage as interim Chief Executive
Officer. As a result of this news, shares of Retrophin fell $0.40 or
almost 4.5%, on unusually heavy trading, to close at $8.62 on October 1,
2014.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Copyright Business Wire 2014